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Preparation and Characterization of Simvastatin Loaded PLGA Microparticles for
Tissue Engineering Applications  
Vijay K. Nandagiri, Clara Muttu, Jacqueline Daly, Zeibun Ramtoola, Gianluca
Ciardelli, Franco Maria Montevecchi 
ABSTRACT 
Simvastatin has been reported to promote osteoblastic activity and inhibit osteoclastic activity.
The successful use of simvastatin to promote in vivo bone formation depends on the local
concentration, and there have been continuous efforts to find an appropriate delivery system for
local delivery. Controlled drug delivery approaches based on microparticles could be a promising
approach for sustained-localized delivery of simvastatin. In this study, simvastatin-loaded PLGA
microparticles were prepared by using a modified single emulsion-solvent evaporation method.
Uniform, spherical simvastatin loaded PLGA microparticles of size below 10μm were produced
by adopting three different drug polymer ratios such as 1:40, 1:20 and 1:10 with encapsulation
efficiency above 85%w/w irrespective to the drug polymer ratio and maximum simvastatin
loading within PLGA microparticles was observed at drug polymer ratio of 1:10. Two stage
release of simvastatin from microparticles was observed for 45 days, illustrating a controlled
release. Simvastatin loaded PLGA microparticles are compatible with hFOB cells and induced in
vitro bio-mineralization during 11 days treatment. These studies illustrate the feasibility of
achieving local delivery of simvastatin to induce in vivo bone formation activity by suitably
engrafting simvastatin loaded microparticles within porous scaffolds. 
 
Keywords: bone tissue engineering, localized delivery, PLGA microparticles, simvastatin,
osteoblastic activity, bio-mineralization. 
1.  INTRODUCTION 
Controlled release technology enables the delivery of a biologically active agent at 
specific time intervals with defined concentration by encapsulating it within a biodegradable 
polymer in the form of a microspheres. Microencapsulation of bioactive substances continues to 
be an important formulation strategy since its inception about 72 years ago. Starting first with the 
aim to protect vitamins from oxidation
1
 it took some decades until polylactic acid (PLA) and later 
its co-polymer, e.g., poly(lactic-co-glycolic acid) (PLGA), were evaluated as biodegradable and 
biocompatible polymers for drug delivery
2-7
.   
PLGA is one of the most extensively investigated polymers for drug delivery and tissue
engineering
8-10
. Many patents and research papers had been reported PLGA as a promising
excipient with high commercial interest. PLGA offers unique properties for drug delivery purposes
such as: world-wide approval for medical use, biodegradability, biocompatibility, ease of
encapsulating wide range of pharmaceutical agents (both hydrophilic and hydrophobic) and
eventually their controlled release. Moreover, its release properties can be easily modified by
varying composition (lactide/glycolide ratio), molecular weight and chemical structure. In this
way, a wide range of in vivo lifetimes of PLGA can be obtained: from 3 weeks to over a year
11-14
. 
In PLGA co-polymers, lactic acid is more hydrophobic than glycolic acid and hence
lactide-rich PLGA copolymers are less hydrophilic, absorb less water and subsequently degrade
more slowly. In this study we used PLGA 50:50 since it is known to be degrade in physiological  
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environment for a period of 4-6 weeks. Furthermore, the type of 
the polymer end group will impact the water-uptake and 
degradation rate of particles. In this study, we used Resomer (RG 
504 H) which is having free carboxyl groups as end groups, which 
may lead to much more swelling of the matrix in compared to 
Resomer (RG 504) which is a capped polymer bearing an aliphatic 
group at the very end group of the polymer chain. The Tg (glass 
transition temperature) of the PLGA copolymers are above the 
physiological temperature of 37º C and hence they are glassy in 
nature. Thus they have a fairly rigid chain structure at room 
temperature, which gives them significant mechanical strength to 
be formulated as drug delivery devices
15
. 
The PLGA co-polymer undergoes degradation in an 
aqueous environment through hydrolytic cleavage of its backbone 
ester linkages. Hydrolysis of the polymer backbone is 
accompanied by gradual erosion of the device, leads to the 
complete degradation of PLGA in physiological environment. The 
microencapsulation of hydrophobic pharmaceutical compounds 
within PLGA by the single emulsion-solvent evaporation method 
has been investigated extensively during the past few decades. The 
basic mechanism involved in formation of particles by this method 
depends on emulsification of a polymeric solution (oil or organic 
phase) with an aqueous continuous phase resulting in the 
formation of o/w emulsion. A schematic diagram of this method is 
shown in Fig.1
16-17
. 
In this method, the hydrophobic drug substance is 
dissolved the polymer/ solvent system to form dispersed phase (oil 
phase) of the emulsion. This dispersed phase is homogenized in 
continuous phase (aqueous phase) which contains a surfactant. 
Homogenozation process is continued until the solvent partitions 
into the aqueous phase and is removed by evaporation. This 
process results in hardened microspheres which contain the active 
drug. Homogenization process had been widely employed to 
disperse the oil phase in aquoues phase with the help of a 
homogenizer, which is equipped with a rotor and stator type blade. 
The rotar blade is attached to a variable high speed motor, with 
which it can rotate and produce high shear forces between stator 
and rotar. This high shear forces result in formation of small 
particles. The O/W emulsion solvent evaporation system has been 
successfully employed to encapsulate poorly water soluble drugs 
including chlorpromazine, prednisolone, and hydrocortisone
18-20
. 
Sansdrap and Moes investigated the influence of several process 
parameters, including agitation rate, surfactant concentrations, 
organic phase volume and drug loading on microspheres of 
nifedipine, a poorly- water soluble calcium-channel blocking 
agent
21
. 
 Simvastatin is a well-known member of the statin family. 
Statins are potent pro-drugs of hydroxy-3-methyl-glutaryl 
coenzyme A (HMG-CoA) reductase inhibitors that block 
conversion of HMG-CoA to mevalonic acid, which is needed for 
cholesterol biosynthesis
22
. Simvastatin has a very low aqueous 
solubility, approximately 1.4 ȝg/mL, because it has a rigid and 
hydrophobic section that is covalently linked to the HMG-like 
moiety. It has an inactive lactone ring in HMG-like portion. 
 Maeda, et al., and Skoglund, et al, reported that, oral 
dosing of rats with simvastatin increased cancellous bone volume 
and formation transverse area of fracture callus as well as 
mechanical properties compared to un-treated control counter 
parts
23-24
. Furthermore, simvastatin has been reported to support 
bone morphogenetic protein (BMP)-induced osteoblast 
differentiation through antagonizing TNF-Į-to-Ras/Rho/ mitogen 
activated protein kinase and augmenting BMP-Smad signalling
25
. 
However, some researchers reported skeptical result of simvastatin 
on bone formation by investigating oral dosing and systemic 
effects of simvastatin
26-27
. However, the main difference between 
systemic and local delivery of simvastatin is effective 
concentration at the desired site. Former is absorbed by gastro-
intestine system and mainly works in the liver and the latter works 
directly on the desired site. With 60 mg dosage forms, serum 
concentrations of simvastatin and simvastatin acid are 18.7 +/- 4.7 
ng/ml and 3.5+/-0.5 ng/ml, respectively. Further, the biological 
half-life of simvastatin acid is 5.9 +/- 0.3 hr
28
. In in vivo 
conditions, the inactive lactone ring of simvastatin is 
enzymatically hydrolyzed to its active hydroxyacid form
29-30
. 
Hence, localized delivery of simvastatin at desired site of bone 
regeneration is required in order to obtain desired therapeutic 
concentrations of simvastain.  
 For local delivery of simvastatin, controlled release 
system based on PLGA microparticles could be a promising 
approach. This paper is focused on preparation and 
characterization of simvastatin loaded PLGA microparticles by 
single emulsion-solvent diffusion technique and characterized in 
terms of surface morphology, encapsulation efficiency and PLGA 
particles loaded with 10% w/w simvastatin were further 
characterized in terms of drug release studies, cell viability test and 
pNPP assay. 
2.  MATERIALS AND METHODS 
 
Preparation of simvastatin loaded PLGA microparticles 
 
 PLGA microparticles were prepared by the modified 
single emulsion-solvent diffusion method as described by Jain, et 
al.,
 31
. Briefly, 4 ml of organic phase constituting 200 mg of PLGA 
dissolved in ethylacetate along with various amounts of simvastatin 
such as 5 mg, 10 mg and 20 mg in order to obtain drug-polymer 
ratio of 1:40, 1:20 and 1:10 respectively. The resulting organic 
phase was added slowly to 25 ml of aqueous phase containing 1% 
(w/v) PVA solution and homogenized at 13,500 rpm at room 
temperature for 3 minutes. The resulting emulsion was then 
transferred into 25 ml of water at 30°C and stirred at 100 rpm with 
hot plate-magnetic stirrer until the solvent was evaporated 
(approximately 3-4 hrs). The resulted PLGA microparticles were 
recovered by centrifugation at 10,000rpm for 15 min at 4 °C, 
washed three times with water to remove residual PVA, re-
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suspended in 1.5ml d dH2O and then lyophilized (Freezone 6, 
Labconco, MO: −57 °C, 0.03 mbar, 24 h). Blank PLGA 
microparticles were prepared in a similar fashion except for the 
lack of drug added in the organic phase. 
 
 
 
Figure 1. A schematic diagram of O/W Emulsion- solvent 
evaporation technique (Adopted from O'Donnell, 1997) 
 
Microparticles characterization 
 
Microparticle yield 
 
 One of the primary requirements for most of the methods 
of microencapsulation is to obtain a high yield of microspheres
31
. 
In this work, we determined the yield of microspheres produced 
using the single emulsion technique. The microsphere yield, 
expressed as a percentage, was calculated as follows  
..............
......(1) 
 The weight of the microparticles, expressed in mg, was 
determined post lyophilization. The weights of the polymer and 
drug, expressed in mg, were the initial amounts of the polymer and 
drug added in the emulsion process.  
 
Encapsulation efficiency and drug loading study 
 
 Drug content in quantitavely weighed 1 mg of PLGA 
microparticles was determined by using a suitably modified HPLC 
method as described by Gupta et al.,
32
. Briefly, the 
chromatographic procedure is as follows: HPLC analysis was 
performed with an Agilent Series 1120 HPLC (Agilent 
Technologies, Wilmington, DE). The chromatographic separations 
were performed using Phenomenex® 100 C18, 5 ȝm, 250 mm X 
4.6 mm. column, at 45ºC, eluted with mobile phase at the flow rate 
of 1.0 mL/min. The mobile phase consisted of acetonitrile and 
50mM potassium di-hydrogen phosphate buffer (65:35, v/v), 
apparent pH adjusted to 4.5±0.1 with phosphoric acid solution, 
filtered through 0.45 ȝm nylon filter and degassed in ultrasonic 
bath prior to use. Column was equilibrated for 5 min. by using 
mobile phase after each run. Each sample was passed through a 
0.22 mm poly tetra fluoro ethylene (PTFE) membrane filter before 
HPLC analysis and each sample analyzed in triplicate and results 
are indicated as an average of three. 
 
 The procedure for analyzing drug loading and 
encapsulation is as follows:1 mg of quantitavely weighed 
microparticles were dissolved in 1 ml of ethyl acetate and vortexed 
for 15 minutes. After agitation, the suspension was centrifuged at 
10,000 rpm for 15min. The supernantant was collected and 
subjected for HPLC analysis for determining the simvastatin 
content as described earlier. Simvastatin loading and encapsulation 
efficiency were determined by Eqs. (2) and (3), respectively. 
 
…………...(2) 
……..(3) 
 
Particle size  
 Microparticle size was determined by laser diffraction 
using a Malvern Master Sizer Sirocco 2000 (Malvern Instrument 
Ltd., Worcestershire, UK). Lyophilized microparticles (<5mg) 
were resuspended in 1 ml of dH2O and particles size recorded in 
triplicate of each batch of microparticles. 
 
Table No. 1. Effect of initial amounts of SIM on average particle size of 
microparticles (mean ± SD, n=3) 
 
 
 
 
 
 
 
 
 
 
 
 
Formulation Average particle size (in μm) 
BLMP 6.4±1.8 
MSIM-01 6.2±1.2 
MSIM-02 6.8±1.6 
MSIM-03 7.2±1.9 
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Table No. 2 Effect of initial amounts of SIM on % Yeild, Drug loading and 
entrapment efficiency (mean ± SD, n=3) 
 
 
 
 
Surface morphology by scanning electron microscopy (sem) 
 
 Microparticles surface morphology was assessed by 
scanning electron microscopy (SEM) Freeze-dried PLGA 
microparticles were fixed onto metallic studs with double-sided 
conductive tape (diameter 12 mm, Oxon, Oxford instruments, UK) 
and coated with gold for 4 minutes under nitrogen atmosphere in a 
blazers of a sputter coating unit (Agar Sputter coater, Agar 
Scientific Ltd., Essex, UK). A LEO 1450 VP (Leo Electron 
microscopy Ltd., Cambridge, UK) scanning electron microscope 
was used with an acceleration voltage of 1.00 kV and a secondary 
detector. The magnification was adjusted till a clear image of the 
surface of the microparticles appeared and the picture was then 
recorded. 
 
 
 
Figure 2. SEM images of freeze dried, a)Blank microparticle; b)MSIM-01;c)MSIM-
02; d)MSIM-03. 
 
 
In vitro simvastatin release studies 
 
 In vitro simvastatin release from optimized PLGA 
microparticles was determined by quantitavely weighing 
lyophilized MSIM microparticles (10 mg) and dispersing in 1 ml of 
phosphate buffer (100 mM, pH 7.4) (PBS) containing 0.02% w/v 
sodium azide as a preservative and incubated at 37°C under gentle 
shaking at 100 rpm. At appropriate intervals, samples were 
centrifuged at 10,000 rpm for 15 min. The supernatant was assayed 
for simvastatin release as it described earlier in of this article, and 
pellet was re-suspended in fresh 1 ml PBS containing 0.02% w/v 
sodium azide. Each microparticle batch was analyzed in triplicate 
and results were expressed as mean ±SD. 
 
hFOB cell culturing 
 
hFOB (ATCC, MA) pre-osteoblastic cells were cultured under 
standard conditions (5% CO2, 37°C). Cells were routinely grown to 
80% confluence in T175 culture flasks (Sarstedt, Ireland) 
containing culture media; a 1:1 ratio of Hams F12 and Dulbecco’s 
modified Eagle’s medium (without phenol red), 10% foetal bovine 
serum, 1% penicillin/streptomycin 10mg/ml (Sigma-Aldrich). 
Expanded hFOB cells of passage 5-15 were harvested with 
trypsin–EDTA treatment, centrifuged and re-suspended in the 
culture medium. 
 
Cell viability studies 
 
 Simvastatin incorparated microparticles and blank 
microparticles formulated by adopting the optimized protocol for 
maximum simvastatin encapsulation efficiency were subjected to 
cell viability study with hFOB cells by alamar blue assay. hFOB 
cells were seeded into two 48 well tissue culture plates (one for 24 
hrs and another for 48hrs ) at a cell density of 50,000 cells per well 
(250 μl of 200,000 cells/ml stock). The plates were incubated at 
37 C in humidified 5% CO2 overnight to allow the cells to attach to 
the bottom of the wells. The medium from each well was replaced 
with 250 ȝl of fresh medium and to each wells 50 ȝl of 
microparticle suspension containing various amounts of 
simvastatin incorporated PLGA microparticles such as 0, 0.1mg, 
1mg and 10 mg was added. The plates were placed on an orbital 
shaker (Biosan, Riga, Latvia) in the incubator at 37ºC and 5% CO2, 
and the assay was carried out at the end of 24h and 48 h, using 
Alamar blue assay kit (Invitrogen, Biosciences, Dublin). After 24 h 
of incubation, the medium from each well from plate 1 was 
replaced with 400 ȝl of fresh medium containing 10% v/v of 
Alamar blue reagent and incubated for 3 h. After 3 h of incubation, 
100 μl of the supernatant from each well was plated in triplicate 
into a 96-well plate and absorbance of the samples was read on a 
spectrometer (Varioskan Flash, version 4.00.53, using SkanIt 
Software 2.4.3 RE for Varioskan Flash soft ware, Thermo 
scientific, Waltham, MA, USA) at 590nm and 610nm. Percentage 
reduction of the Alamar blue solution was determined according to 
the manufacture’s specifications. The same procedure was repeated 
for 2
nd
 plate after 48 hrs of incubation. 
Formulation
name 
Wt of 
SIM used
(in mg) 
Wt of 
PLGA 
used (in
mg) 
% Yield of 
microparticl
s 
% SIM 
loading 
Encapsulation
Efficiency(%
BLMP 0 200 92.5±2.5 - - 
MSIM-01 5 200 90±0.75 2.31±0.1 85.31±3.8 
MISIM-02 10 200 87±1.7 4.68±0.14 85.27±2.5 
MSIM-03 20 200 85±1.4 9.94±0.22 92.2±2.1 
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Figure 3. HPLC chromatogram of simvastatin extracted from microparticles. 
 
 
 
Figure 4. HPLC chromatogram of simvastatin released from microparticles. (Day 
2.) 
 
 
 
Figure 5. HPLC chromatogram of simvastatin released from microparticles (Day 
10.) mixed with pure simvastatin in ethylacetate just before the analysis. 
 
In vitro bio-mineralization test 
 
 In vitro bio-mineralization induced by various amounts of 
MSIM-03 on hFOB cells was assessed by using alkaline 
phosphatase activity (ALP) assay by conveniently modifying the 
procedure described by Gentile et al.,
33
. Briefly, hFOB cells were 
seeded into two 48 well tissue culture plates (one each for 2 d and 
for 11d ) at a cell density of 50,000 cells per well (250 μl of 
200,000 cells/ml stock). The plates were incubated at 37°C in 
humidified 5% CO2 overnight to allow the cells to attach to the 
bottom of the wells. 
 
 
 
 
Figure 6 Cumulative % release of simvastatin from microparticles in PBS at 37 ºC 
(mean±SD, n=3) 
 
 
Figure 7. Effect of blank and simvastatin loaded microparticle treatment on cell 
viability of hFOB cells. Bars indicate the average cell number (mean ± SD; n=3; *is 
p<0.05, ** is p<0.0001) 
 
  The medium from each well was replaced with 250 ȝl of 
fresh medium and to each wells 50 ȝl of microparticle suspension 
containing various amounts of simvastatin incorporated PLGA 
microparticles such as 0, 0.1mg, 1mg and 10 mg was added. The 
plate was placed on an orbital shaker (Biosan, Riga, Latvia) in an 
incubator at 37ºC and 5% CO2, and the assay was carried out at the 
end of 2 d and 11 d, using the p-Nitrophenyl Phosphate disodium 
salt (pNPP reagent) (Sigma, Ireland). After 2 d of incubation, the 
medium from each well from plate 1 was removed and each well 
and cell layer was washed two-three times with 300 μl of PBS, and 
replaced with 400 ȝl of PBS containing 20 % v/v of pNPP and 
incubated for 15 min in an incubator at 37ºC and 5% CO2. After 15 
min of incubation, 100 μl of the supernatant from each well was 
plated in triplicate into a 96-well plate and absorbance of the 
samples was read on a spectrometer (Varioskan Flash, version 
4.00.53, using SkanIt Software 2.4.3 RE for Varioskan Flash soft 
ware, Thermo scientific, Waltham, MA, USA) at 405 nm. For plate 
2, media was replenished every 2-3 days for 11 days by simply 
aspiring 250μl from each well and replacing with fresh equivalent 
medium. At the end of 11 days, pNPP activity was assessed as 
described earlier. Enzyme activity was expressed as a function of 
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OD at 405nm. The mean and the standard deviation were obtained 
from three different experiments
34
. 
 
Figure 8.The ALP activity of hFOB cells in response to the treatment of MSIM . 
Bars indicate the average OD values (mean ± SD; n=3; *is p<0.05, ** is p<0.0001) 
 
Statistical analysis 
 
 Experiments were run in triplicate for each sample. All 
data were expressed as mean ± SD for n=3. Statistical analysis was 
determined by using Analyse-it v2.22 software. The statistical 
differences between groups were calculated using Kruskal-Wallis 
One Way Analysis of Variance on Ranks (ANOVA). Statistical 
significance was declared as significant(*) at p<0.05, and very 
significant(**) at p<0.0001. 
 
3.  RESULTS AND DISCUSSION 
 
Particle size and Surface morphology 
 
 For encapsulating hydrophobic or poorly water-soluble 
drugs with PLGA microparticles, the oil-in-water (o/w) method is 
frequently used as this method is the simplest and easy to prepare 
microparticles
35
. The particle size is one of the important 
characteristics of the drug loaded microparticles as it could affect 
drug release properties of microparticles. Particle size 
determination studies reveal that the microparticles produced were 
uniform with a size range of 5-8 μm. and loading of simvastatin 
has not altered the particle size as represented in Table.1. 
Furthermore, it is evident from SEM images that the microparticles 
produced were spherical in shape with smooth surfaces 
indicating.that the loading of the drug did not lead to any 
significant changes in surface of the microparticles. 
 
 In general the size of microparticle formed depends on the 
extent of separation of oil phase containing polymer in continuous 
phase into small individual droplets, which can be achieved by 
applying shear forces. In this study, we used to homogenization 
process to induce the shear forces. Furthermore, 1%w/v of PVA 
was adopted as a stabilizer for microparticle formation which can 
reduce the interfacial tension of organic and water phase. The 
droplet break-up during the homogenization process is due to the 
turbulent flow of organic phase within the aqueous phase. This 
turbulent flow is controlled by inertial forces which are dependent 
on the viscosity of the polymer phase
36
. Hence, in this study, we 
used an optimum concentration of 50 mg/ml of PLGA to make the 
microparticles. Poly vinyl alcohol (PVA) is the most commonly 
used emulsifier in PLGA microparticle formulation as it is 
associated with the formation of relatively small particles with 
uniform size distribution
37
. 
 
 Furthermore, the concentration of PVA used in 
continuous phase during emulsification influences the particle size. 
Increasing the PVA concentration or its molecular weight had been 
reported to result in smaller microparticles
38
. However, higher 
PVA concentrations in continuous phase may hinder the complete 
separation of nascent droplets due to bridging effect at overly high 
PVA concentration and may result in formation of a larger number 
of aggregated microparticles during solidification
39
. Hence in this 
study, poly vinyl alcohol (Mw: 30-70 kD, >87-90% hydrolized) at 
a concentration of 1%w/v was considered to make PLGA 
microparticles. The scanning electron micrograph images of the 
microparticles revealed their regular spherical shape, smooth 
surface and no aggregation. No difference was observed in the 
morphological properties of microparticles due to presence of the 
simvastatin (Fig. 2). 
 
Encapsulation efficiency and simvastatin loading 
 
 The RP-HPLC analysis for the simvastatin loaded 
microspheres dissolved in ethyl acetate for determining simvastatin 
loading and encapsulation efficiency displayed a characteristic 
peak of simvastatin at around 7.9 min. which is similar to that of 
pure simvastatin (Fig. 3). 
 
 All microparticle formulations had high yield above 85% 
w/w recovery with respect to the initial amounts of polymer and 
drug used in the microparticle formulations and no significant 
differences were observed with varying amount of simvastatin 
added to the formulations. The results disclosed a maximum 
encapsulation (above 85%) of simvastatin within PLGA 
microparticles (Table. 2) which could be attributed to the 
hydrophobicity of the simvastain and very low water 
solubility,(solubility of simvastatin in PBS (1.1ȝg/ml))29,40. 
 
 Simvastatin loading within PLGA microparticles was 
increased with the increase in initial amount of the formulation. 
However, maximum encapsulation of simvastatin of above 92% 
was observed 1:10 drug polymer ratio used for making 
microparticles. Owing to the dosage requirements and detection 
limitations we optimized 10% w/w loading of simvastatin in PLGA 
microparticles i.e. MSIM-03 as a suitable formulation for further 
studies. 
 
Release studies 
 Quantification of released simvastatin from PLGA 
microparticles was performed by RP-HPLC method. In general, 
HPLC system consists of a continuous phase and a mobile phase. 
The mobile phase acts as a carrier for the sample solution. The 
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columns are packed with the stationary phase, which was immobile 
and immiscible to the mobile phase forced through it. In Reverse 
Phase HPLC system, the retention of solute in column is as a result 
of the interactions between non polar components of the solutes 
and the non polar stationary phase. Therefore the more hydrophilic 
moieties elute faster than the hydrophobic ones. The RP-HPLC 
chromatogram for released simvastatin show a shift in retention 
time from 7.9 min. to 5.7 min. and a peak was observed at around 
3.5.min., and at around 1.5 min. which kept increasing over time 
which could be due to simvastatin-acid, the active metabolite of 
simvastatin. This is the open hydroxy acid form of the closed 
lactone form of simvastatin and is more hydrophilic in nature (Fig. 
4 & Fig. 5). 
 
 The lactone drug may have been hydrolyzed and 
consequently simvastatin acid, which is more hydrophilic in nature 
might have been detected before the characteristic peak of 
simvastatin. The AUC (area under curve) which was used to 
quantify the released simvastatin was the sum of all peaks which 
were observed during the chromatographic analysis
29,40
. 
 
 Furthermore, for potential detection of simvastatin (which 
is not hydrolyzed) in release medium, 0.5 ml drug release 
supernatant was mixed with of 0.5 ml of ethyl acetate and 
subjected for HPLC analysis. Ethyl acetate was added with an idea 
to dissolve simvastatin if present in the sample. But, there was no 
peak observed at the retention time of 7.9 min. indicating that the 
released simvastatin is hydrolyzed in PBS. Blank PLGA 
microparticles were also subjected for release study similar to 
simvastatin loaded PLGA microparticles to check for peak if any, 
from polymer degradation. But these results confirmed the absence 
of simvastatin and simvastatin acid peaks. Moreover, HPLC 
analysis for simvastatin released samples on day 10 were mixed 
with of known amounts of simvastatin dissolved in ethyl acetate 
and mixed just before the analysis, was also performed and 
resulted a characteristic peak of simvastatin (at retention time 
around 7.9 min ) and subsequent peaks of simvastatin-acid in a 
similar fashion(Fig.6). 
 
 Generally speaking, hydrophobic drug release from 
microparticle carrier systems occurs via diffusion down the 
concentration gradient. The homogenous distribution of 
hydrophobic drug within the polymeric matrix would result during 
the microparticles formulation, owing to its solubility in solvent, 
resulting in the formation of a monolithic solution system. Hence, 
as drug begins to release from the surface of the matrix, a 
concentration gradient is established to provide the driving force 
for drug diffusion from the interior of the matrix towards the 
surface for subsequent release
41
. 
 The cumulative release versus time profiles of simvastatin 
from PLGA microparticles in PBS buffer (pH 7.4) was represented 
in Fig.7. reveals an initial slow release of simvastatin from 
microparticles which could be attributed to the hydrophobicity of 
simvastatin. Moreover, the interaction of hydrophobic drug 
molecules with the polymer matrix via hydrophobic binding forces 
or of amine-groups with the polymer carboxyl groups by ionic 
bonds might cause a trapping of the drug inside the particles and 
therefore, a slower release
42
.   
 
 During first 24 hrs of release study, only 1%w/w of 
encapsulated simvastatin was released from micro-particles. 
Following to this, the release of simvastatin was increased to 
around 5 % w/w of encapsulated simvastatin (from day 1- day 2 of 
release studies), which is probably due to the diffusion of drug 
which is present at the surface of the microparticles. The presence 
of drug crystals at the surface of particles could be attributed to the 
solvent flux out of the oil phase during the solvent evaporation step 
of microparticle formation. The solvent flux might transport drug 
to the particle surface. Once the solvent partitioned into the water 
phase its dissolving power would have disappeared resulting in 
either precipitation of drug at the particle surface or in the 
suspension medium. Since simvastatin is hydrophobic in nature, it 
would have adsorbed at the surface of microparticles 
43
. After this 
initial slow release, there was a rapid release of simvastatin from 
the microparticles (from day 2-day 7 of the release study) which 
could be attributed hydrolytic random chain scission process of the 
polymer resulting in the formation of pores within the 
microparticles. The pores which were formed would have resulted 
an increase in water uptake within the microparticles. During this 
release phase, the drug release is governed by diffusion-controlled 
mechanism through a network of water filled pores and channels. 
During this process of drug release, the molecular weight of the 
polymer decreases significantly, but no appreciable weight loss and 
no soluble monomer products were formed
44-46
. Around 40% w/w 
of encapsulated drug was released during this phase. Following to 
this rapid release phase, a more controlled release of drug from 
microparticles was observed (during day 7-day 45 of the release 
study) which could be attributed to the bulk erosion of the 
microspheres by hydrolysis of the polymer’s ester bond linkages. 
During this release phase, there would be a rapid loss of polymeric 
mass due to the formation of soluble oligomeric and monomeric 
products of bulk polymer. Finally, soluble monomeric products 
formed were degraded into soluble oligomeric units resulting a 
complete release of encapsulated drug
47-49
(around 96% w/w of 
encapsulated drug was released towards the end of 45 days release 
study).  
 
Cell viability test 
 
 The effect of BLMP and MSIM-03 on hFOB cell viability 
was represented in Fig 8. It is evident from the histogram that there 
is a dose dependent reduction in cell number when hFOB cells are 
treated with blank PLGA microparticles and MSIM-03 particles 
after 1 d and 2 d of incubation. However, this treatment is not 
having any effect on cell proliferation which is evident from 
increased cell number after 2 d. Moreover, in case of cells treated 
with MSIM-03 particles, a slight increase in cell number observed 
in compare with that of blank microparticles, which could be 
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attributed to released simvastatin which would have promoted the 
cell proliferation rate and differentiation.  
 
In vitro bio-mineralization 
 
 The ALP activity of hFOB cells in response to the 
treatment of MSIM-03 particles. The histogram was plotted by 
taking number of days after treatment on X-axis and difference in 
OD at 405 nm between blank wells and treated wells. The results 
reveal that MSIM-03 induced in vitro bio-mineralization as the 
treatment time increased which could be attributed to the release of 
simvastatin from MSIM-03 microparticles. ALP is a good marker 
for the differentiation of osteoblastic cells. The increased 
expression of ALP levels after 11 days treatment of MSIM-03 on 
hFOB cells confirms release and the activity of encapsulated 
simvastatin. 
 
4.  CONCLUSION 
 
 In this study, we successfully incorporated simvastatin 
within biodegradable PLGA microparticles. The resulted 
microparticles displayed uniform spherical shape, size and 
controlled release of simvastatin for 45 days. Release of 
simvastatin from PLGA microparticles displayed two stages 
release: During first stage, initially there was a slow release 
mediated by diffusion of adsorbed simvastatin through the polymer 
network followed by a rapid release mediated by the diffusion of 
simvastatin through the fluid-filled within the particles as a result 
of pores formed within the particles. During second stage, a more 
controlled release was observed which could be attributed to the 
physical bulk erosion and/or hydrolysis of the polymer and finally 
complete degradation of polymer after 6 weeks of release study. 
Furthermore, simvastatin loaded PLGA microparticles treatment 
on hFOB cells induced in vitro bio-mineralization which indicates 
that the developed delivery system can be potentially applied for 
the purpose of bone regeneration by suitably incorporating within 
porous 3 D scaffolds for the purpose of spatio-temporal release of 
simvastatin.  
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